Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While Thymosin Beta-4 works as an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
Thymosin Beta-4
TMSB4X
Tirzepatide
Not assigned in the current dataset.
Thymosin Beta-4 and Tirzepatide are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Cardiovascular health contexts, while Thymosin Beta-4 is more of a signal peptide and Cytokine peptide and Tirzepatide is better described as a metabolic peptide and Hormone peptide. Their biological logic is quite different: Thymosin Beta-4 is a signaling modulator and a protein interaction inhibitor, whereas Tirzepatide is a receptor agonist and a hormone analog. Thymosin Beta-4 has a more natural endogenous origin, while Tirzepatide is closer to synthetic analog background and their development context also differs, with Thymosin Beta-4 in Clinical phase 2 while Tirzepatide is approved. Thymosin Beta-4 takes the form of a linear peptide, whereas Tirzepatide is closer to a peptide conjugate, Thymosin Beta-4 carries acetylation features, while Tirzepatide instead reflects lipidation and d-amino acid substitution changes; while their sequence patterns also diverge, with Thymosin Beta-4 showing protein-mimetic sequence features and Tirzepatide showing alpha-helical domain features.